TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Brief Summary: To evaluate the efficacy and safety of pregabalin administered twice a day compared to placebo in reducing pain in subjects with painful diabetic peripheral neuropathy.


Options:
A: Arm Label: Burst SCS; Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation, Device: SCS implant | Arm Label: Sham SCS; Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation, Device: SCS implant | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst SCS, Sham SCS | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst SCS, Sham SCS | Intervention Type: DEVICE; Name: SCS implant; Assigned to Arm(s): Burst SCS, Sham SCS
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Spinal Cord Stimulator | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Spinal Cord Stimulator | Intervention Type: DEVICE; Name: PINS Spinal Cord Stimulator; Assigned to Arm(s): Control, Experimental
C: Arm Label: Active Lead (AL); Type: ACTIVE_COMPARATOR; Interventions: Device: Nevro Senza System (HF10 Therapy) | Arm Label: Sham Lead (SL); Type: SHAM_COMPARATOR; Interventions: Device: Nevro Senza System (HF10 Therapy) | Intervention Type: DEVICE; Name: Nevro Senza System (HF10 Therapy); Assigned to Arm(s): Active Lead (AL), Sham Lead (SL)
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States
Brief Summary: The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.


Options:
A: Arm Label: 5 milligrams (mg) Tadalafil; Type: EXPERIMENTAL; Interventions: Drug: Tadalafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): 5 milligrams (mg) Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Viagra; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Tadalafil; Type: EXPERIMENTAL; Interventions: Drug: Tadalafil, Drug: Finasteride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Finasteride | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Finasteride; Assigned to Arm(s): Placebo, Tadalafil
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo capsule | Arm Label: Tadalafil 5 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Tadalafil 5 mg | Arm Label: Tamsulosin 0.4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tadalafil 5 mg; Assigned to Arm(s): Tadalafil 5 milligram (mg) | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin 0.4 mg | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: Champix plus counselling; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: counselling alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselling alone | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix plus counselling | Intervention Type: BEHAVIORAL; Name: Counselling alone; Assigned to Arm(s): counselling alone
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline + Patch Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline Only Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline + Patch Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch | Arm Label: Varenicline Only Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration | Intervention Type: OTHER; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: OTHER; Name: Placebo Pill; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Standard Duration
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: virtual reality exposure therapy (VRET); Type: EXPERIMENTAL; Interventions: Other: virtual reality exposure treatment | Arm Label: cognitive and behavioral approaches therapy without VRET; Type: EXPERIMENTAL; Interventions: Other: cognitive and behavioral approaches therapy | Intervention Type: OTHER; Name: virtual reality exposure treatment; Assigned to Arm(s): virtual reality exposure therapy (VRET) | Intervention Type: OTHER; Name: cognitive and behavioral approaches therapy; Assigned to Arm(s): cognitive and behavioral approaches therapy without VRET
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C
D: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: E-cigarette free access; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette free access | Arm Label: E-cigarette/NRT/Zyban/Chantix Choice; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette/NRT/Zyban/Chantix Choice | Arm Label: Outcome Incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Outcome Incentive arm | Arm Label: Loss framing incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: E-cigarette free access; Assigned to Arm(s): E-cigarette free access | Intervention Type: BEHAVIORAL; Name: E-cigarette/NRT/Zyban/Chantix Choice; Assigned to Arm(s): E-cigarette/NRT/Zyban/Chantix Choice | Intervention Type: BEHAVIORAL; Name: Outcome Incentive arm; Assigned to Arm(s): Outcome Incentive arm | Intervention Type: BEHAVIORAL; Name: Loss framing incentive arm; Assigned to Arm(s): Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
D: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo
B: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
C: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation
Brief Summary: The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: B